CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy

References

• Kim Y, Clements DR, Sterea AM, Jang HW, Gujar SA. PWK L: dendritic cells in oncolytic virus-based anti-cancer therapy. In: Chiocca EA, Lamfers MLM, Eds. Viruses. 2015. Vol. 7. p. 6506–6525. Ocolytic Viruses: Viruses / MDPI AG, Basel, Switzerland. doi:10.3390/v7122953.
   Google Scholar
• Steinman RM. Hemmi H: dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol. 2006;311:17–58.
   PubMed Web of Science ®Google Scholar
• Fong L. Engleman EG: dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245–273. doi:10.1146/annurev.immunol.18.1.245.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D. Sotomayor EM: immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296. doi:10.1146/annurev.immunol.25.022106.141609.
   PubMed Web of Science ®Google Scholar
• Gervais A, Leveque J, Bouet-Toussaint F, Burtin F, Lesimple T, Sulpice L, Patard JJ, Genetet N. Catros-Quemener V: dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res. 2005;7:R326–335. doi:10.1186/bcr1001.
   PubMed Web of Science ®Google Scholar
• Cerundolo V, Hermans IF. Salio M: dendritic cells: a journey from laboratory to clinic. Nat Immunol. 2004;5:7–10. doi:10.1038/ni0104-7.
   PubMed Web of Science ®Google Scholar
• Wong KK, Li WA, Mooney DJ. Dranoff G: advances in Therapeutic Cancer Vaccines. Adv Immunol. 2016;130:191–249. doi:10.1016/bs.ai.2015.12.001.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ. Punt CJ: dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol. 2008;66:118–134. doi:10.1016/j.critrevonc.2007.12.007.
   PubMed Web of Science ®Google Scholar
• Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, et al. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016;64:167–174. doi:10.1016/j.ejca.2016.06.008.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, Grabbe S, Rittgen W, Edler L, Sucker A, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563–570. doi:10.1093/annonc/mdj138.
   PubMed Web of Science ®Google Scholar
• Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, Lin SZ, Chen CC, Harn HJ, Liu CL, Lee WY, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg. 2012;77:736–744. doi:10.1016/j.wneu.2011.08.020.
   PubMed Web of Science ®Google Scholar
• Sakai K, Shimodaira S, Maejima S, Sano K, Higuchi Y, Koya T, Sugiyama H. Kazuhiro Hongo: clinical effect and immunological response in patients with advanced malignant glioma treated with WT1-pulsed dendritic cell-based immunotherapy: A report of two cases. Interdisciplinary Neurosurgery. 2017;9:24–29. doi:10.1016/j.inat.2017.02.004.
   Google Scholar
• Cui Y, Yang X, Zhu W, Li J, Wu X. Pang Y: immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett. 2013;6:537–541. doi:10.3892/ol.2013.1376.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Q, Li WF, Wang HY, Zhang HJ. Zhu JJ: different antitumor immunity roles of cytokine activated T lymphocytes from naive murine splenocytes and from dendritic cells-based vaccine primed splenocytes: implications for adoptive immunotherapy. Eksp Onkol. 2004;26:55–62.
   PubMed Web of Science ®Google Scholar
• Chang XH, Cheng HY, Cheng YX, Ye X, Guo HF, Fu TY, Zhang L, Zhang G. Cui H: [specific immune cell therapy against ovarian cancer in vivo and in vitro]. Ai Zheng. 2008;27:1244–1250.
   PubMedGoogle Scholar
• Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M. Kaibara N: an elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res. 2000;20:4489–4493.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T. Okumura K: transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001;91:964–971.
   PubMed Web of Science ®Google Scholar
• Ghellal A, Li C, Hayes M, Byrne G, Bundred N. Kumar S: prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res. 2000;20:4413–4418.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Gronberg-Vaha-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vaha-Koskela M. Hemminki A: adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor. Cancer Immunol Res. 2015;3:915–925. doi:10.1158/2326-6066.CIR-14-0220-T.
   PubMed Web of Science ®Google Scholar
• Lawler SE, Speranza MC, Cho CF. Chiocca EA: oncolytic viruses in cancer treatment: A review. JAMA Oncol. 2017;3:841–849. doi:10.1001/jamaoncol.2016.2064.
   PubMed Web of Science ®Google Scholar
• Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y. Noelle RJ: molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152–172. doi:10.1111/j.1600-065X.2009.00782.x.
   PubMed Web of Science ®Google Scholar
• Taipale K, Liikanen I, Juhila J, Turkki R, Tahtinen S, Kankainen M, Vassilev L, Ristimaki A, Koski A, Kanerva A, et al. Chronic activation of innate immunity correlates with poor prognosis in cancer patients treated with oncolytic adenovirus. Mol Ther. 2016;24:175–183. doi:10.1038/mt.2015.143.
   PubMed Web of Science ®Google Scholar
• Parviainen S, Ahonen M, Diaconu I, Hirvinen M, Karttunen A, Vaha-Koskela M, Hemminki A. Cerullo V: CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Ther. 2014;21:195–204. doi:10.1038/gt.2013.73.
   PubMed Web of Science ®Google Scholar
• Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T, Kairemo K, Laasonen L, Partanen K, Kangasniemi L, et al. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther. 2012;20:1821–1830. doi:10.1038/mt.2012.115.
   PubMed Web of Science ®Google Scholar
• Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A. Hemminki A: tNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology. 2018;7. doi:10.1080/2162402X.2017.1412902.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19:3280–3287. doi:10.1200/JCO.2001.19.13.3280.
   PubMed Web of Science ®Google Scholar
• Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 2012;72:2327–2338. doi:10.1158/0008-5472.CAN-11-2975.
   PubMed Web of Science ®Google Scholar
• Sun Y, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C. Prieto J: in vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther. 2000;7:1467–1476. doi:10.1038/sj.gt.3301264.
   PubMed Web of Science ®Google Scholar
• Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, Oksanen M, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012;72:1621–1631. doi:10.1158/0008-5472.CAN-11-3001.
   PubMed Web of Science ®Google Scholar
• Alemany R, Balague C. Curiel DT: replicative adenoviruses for cancer therapy. Nat Biotechnol. 2000;18:723–727. doi:10.1038/77283.
   PubMed Web of Science ®Google Scholar
• Dummer R, Hassel JC, Fellenberg F, Eichmuller S, Maier T, Slos P, Acres B, Bleuzen P, Bataille V, Squiban P, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood. 2004;104:1631–1638. doi:10.1182/blood-2004-01-0360.
   PubMed Web of Science ®Google Scholar
• Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol. 2004;22:1389–1397. doi:10.1200/JCO.2004.04.059.
   PubMed Web of Science ®Google Scholar
• Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, et al. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther. 2011;18:288–296. doi:10.1038/cgt.2010.79.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788. doi:10.1200/JCO.2014.58.3377.
   PubMed Web of Science ®Google Scholar
• Zafar S, Parviainen S, Siurala M, Hemminki O, Havunen R, Tahtinen S, Bramante S, Vassilev L, Wang H, Lieber A, et al. Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. Oncoimmunology. 2017;6:e1265717. doi:10.1080/2162402X.2016.1265717.
   PubMed Web of Science ®Google Scholar
• Wen FT, Thisted RA, Rowley DA. Schreiber H: A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology. 2012;1:172–178. doi:10.4161/onci.1.2.18311.
   PubMed Web of Science ®Google Scholar
• Mosier DE, Gulizia RJ, Baird SM. Wilson DB: transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 1988;335:256–259. doi:10.1038/335256a0.
   PubMed Web of Science ®Google Scholar
• Brehm MA, Shultz LD. Greiner DL: humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes. 2010;17:120–125. doi:10.1097/MED.0b013e328337282f.
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263–274. doi:10.1038/nrc1586.
   PubMed Web of Science ®Google Scholar
• Banchereau J. Palucka AK: dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296–306. doi:10.1038/nri1592.
   PubMed Web of Science ®Google Scholar
• Lim DS, Kim JH, Lee DS, Yoon CH. Bae YS: DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol Immunother. 2007;56:1817–1829. doi:10.1007/s00262-007-0325-0.
   PubMed Web of Science ®Google Scholar
• Amoils KD. Bezwoda WR: TGF-beta 1 mRNA expression in clinical breast cancer and its relationship to ER mRNA expression. Breast Cancer Res Treat. 1997;42:95–101.
   PubMed Web of Science ®Google Scholar
• Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, Chouaib S. Mami-Chouaib F: quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer. 1998;77:7–12.
   PubMed Web of Science ®Google Scholar
• Conrad CT, Ernst NR, Dummer W, Brocker EB. Becker JC: differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J Exp Clin Cancer Res. 1999;18:225–232.
   PubMed Web of Science ®Google Scholar
• Yang L. Carbone DP: tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 2004;92:13–27. doi:10.1016/S0065-230X(04)92002-7.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D. Carbone DP: production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096–1103.
   PubMed Web of Science ®Google Scholar
• Lindau D, Gielen P, Kroesen M, Wesseling P. Adema GJ: the immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138:105–115. doi:10.1111/imm.12036.
   PubMed Web of Science ®Google Scholar
• Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL. Akporiaye ET: transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 2003;63:1860–1864.
   PubMed Web of Science ®Google Scholar
• Korniluk A, Kemona H. Dymicka-Piekarska V: multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol. 2014;35:9447–9457. doi:10.1007/s13277-014-2407-x.
   PubMed Web of Science ®Google Scholar
• Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I. Banchereau J: activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263–1272.
   PubMed Web of Science ®Google Scholar
• Peguet-Navarro J, Dalbiez-Gauthier C, Rattis FM, Van Kooten C, Banchereau J. Schmitt D: functional expression of CD40 antigen on human epidermal langerhans cells. J Immunol. 1995;155:4241–4247.
   PubMed Web of Science ®Google Scholar
• Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A. Alber G: ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184:747–752.
   PubMed Web of Science ®Google Scholar
• Grewal IS. Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111–135. doi:10.1146/annurev.immunol.16.1.111.
   PubMed Web of Science ®Google Scholar
• Grewal IS, Xu J. Flavell RA: impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature. 1995;378:617–620. doi:10.1038/378617a0.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612–1616. doi:10.1126/science.1198443.
   PubMed Web of Science ®Google Scholar
• Ruter J, Antonia SJ, Burris HA, Huhn RD. Vonderheide RH: immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010;10:983–993. doi:10.4161/cbt.10.10.13251.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Rousseau RF, Yotnda P, Mei Z, Dotti G, Rill D, Hurwitz R, Marini F, Andreeff M. Brenner MK: autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001;12:659–670. doi:10.1089/104303401300057360.
   PubMed Web of Science ®Google Scholar
• Loskog A, Maleka A, Mangsbo S, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsdottir M, Sundin A, Ahlstrom H, et al. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer. 2016;114:872–880. doi:10.1038/bjc.2016.42.
   PubMed Web of Science ®Google Scholar
• Cerullo V, Vaha-Koskela M. Hemminki A: oncolytic adenoviruses: A potent form of tumor immunovirotherapy. Oncoimmunology. 2012;1:979–981. doi:10.4161/onci.20172.
   PubMed Web of Science ®Google Scholar
• Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010;18:1874–1884. doi:10.1038/mt.2010.161.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y, Hara T, Hashimoto N, Takahashi M, Shimokata K, et al. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Cancer Gene Ther. 2001;8:421–429. doi:10.1038/sj.cgt.7700320.
   PubMed Web of Science ®Google Scholar
• Danese S, Sans M. Fiocchi C: the CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut. 2004;53:1035–1043.
   PubMed Web of Science ®Google Scholar
• Bishop GA, Moore CR, Xie P, Stunz LL. Kraus ZJ: TRAF proteins in CD40 signaling. Adv Exp Med Biol. 2007;597:131–151. doi:10.1007/978-0-387-70630-6_11.
   PubMed Web of Science ®Google Scholar